Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesZoetis Inc

Zoetis Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
82.315 USD -0.14 ( 0.18%)
Last update at 2026-11-11T20:53:00Z
VOLUME
3465292
Market Cap
30343.01M
P/E
11.98

Momentum Score

…

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
80.79
Low
82.37
High
52 Week Price Range
70.98
Low
145.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
82.46
Dividend Yield
2.80%
Revenue TTM
9525.00M
Revenue Per Share
22.14
Gross Profit TTM
6833.00M
Debt / Equity
2.85
ROE
64.91%
Net Debt
7181.00M
ROCE
27.07%
Diluted EPS TTM
6.13

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 3360.00M 3133.00M 2936.00M 2656.00M 2488.00M
Minority interest 0.00M -10.00M 4.00M 3.00M -3.00M
Net income 2673.00M 2486.00M 2344.00M 2114.00M 2037.00M
Selling general administrative 2378.00M 2016.00M 1870.00M 2009.00M 2001.00M
Selling and marketing expenses - 302.00M 281.00M - -
Gross profit 6673.00M 6396.00M 5834.00M 5626.00M 5473.00M
Reconciled depreciation 487.00M 497.00M 491.00M 465.00M 161.00M
Ebit 3582.00M 3375.00M 3194.00M 2888.00M 2755.00M
Ebitda 4069.00M 3872.00M 3685.00M 3038.00M 2916.00M
Depreciation and amortization 487.00M 497.00M 491.00M 150.00M 161.00M
Non operating income net other - - - -40.00M -48.00M
Operating income 3597.00M 3392.00M 3069.00M 2888.00M 2755.00M
Other operating expenses 5870.00M 5864.00M 5475.00M 5152.00M 4973.00M
Interest expense 243.00M 242.00M 258.00M 221.00M 224.00M
Tax provision 687.00M 637.00M 596.00M 545.00M 454.00M
Interest income 93.00M 106.00M 105.00M 50.00M 6.00M
Net interest income -129.00M -119.00M -134.00M -171.00M -224.00M
Non recurring - - - 11.00M 43.00M
Income tax expense 687.00M 637.00M 596.00M 545.00M 454.00M
Total revenue 9467.00M 9256.00M 8544.00M 8080.00M 7776.00M
Total operating expenses 3076.00M 3004.00M 2765.00M 2698.00M 2670.00M
Cost of revenue 2794.00M 2860.00M 2710.00M 2454.00M 2303.00M
Total other income expense net -237.00M -259.00M -133.00M -232.00M -267.00M
Net income from continuing ops 2673.00M 2496.00M 2340.00M 2111.00M 2034.00M
Net income applicable to common shares 2673.00M 2486.00M 2344.00M 2114.00M 2037.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15467.00M 14237.00M 14286.00M 14925.00M 13900.00M
Intangible assets 998.00M 1127.00M 1338.00M 1380.00M 1474.00M
Other current assets 436.00M 379.00M 436.00M 365.00M 389.00M
Total liab 12136.00M 9467.00M 9295.00M 10522.00M 9356.00M
Total stockholder equity 3331.00M 4770.00M 4997.00M 4405.00M 4543.00M
Deferred long term liab - - - 142.00M 320.00M
Other current liab 1537.00M 1536.00M 1365.00M 1410.00M 1361.00M
Common stock 5.00M 5.00M 5.00M 5.00M 5.00M
Capital stock 5.00M 5.00M 5.00M 5.00M 5.00M
Retained earnings 13744.00M 11968.00M 10295.00M 8668.00M 7186.00M
Other liab - - - 585.00M 811.00M
Good will 2767.00M 2724.00M 2759.00M 2746.00M 2682.00M
Other assets 956.00M 781.00M 403.00M 320.00M 211.00M
Cash 2312.00M 1985.00M 2039.00M 3577.00M 3482.00M
Cash and equivalents 2310.00M 1985.00M 2039.00M 3577.00M 3482.00M
Total current liabilities 2235.00M 3412.00M 1889.00M 3167.00M 1797.00M
Current deferred revenue 11.00M - 5.00M - -
Net debt 7181.00M 4759.00M 4716.00M 4513.00M 3261.00M
Short term debt 53.00M 1350.00M 3.00M 1352.00M 0.00M
Short long term debt - 1350.00M 3.00M 1352.00M -
Short long term debt total 9493.00M 6744.00M 6755.00M 8090.00M 6743.00M
Other stockholder equity -9584.00M -6263.00M -4464.00M -3451.00M -1884.00M
Property plant equipment 3978.00M 3619.00M 3443.00M 2753.00M 2422.00M
Total current assets 6768.00M 5986.00M 6343.00M 7506.00M 6930.00M
Net tangible assets - - - 279.00M 387.00M
Short term investments - 2.00M - - -
Net receivables 1590.00M 1316.00M 1304.00M 1215.00M 1133.00M
Long term debt 9042.00M 5220.00M 6564.00M 6552.00M 6592.00M
Inventory 2430.00M 2306.00M 2564.00M 2345.00M 1923.00M
Accounts payable 487.00M 433.00M 411.00M 405.00M 436.00M
Noncontrolling interest in consolidated entity - - - -2.00M 1.00M
Accumulated other comprehensive income -834.00M -940.00M -839.00M -817.00M -764.00M
Common stock total equity - - - 5.00M 5.00M
Retained earnings total equity - - - 8668.00M 7186.00M
Treasury stock - - - -4539.00M -2952.00M
Non currrent assets other 328.00M 220.00M 206.00M 147.00M 111.00M
Non current assets total 8699.00M 8251.00M 7943.00M 7419.00M 6970.00M
Capital lease obligations 196.00M 174.00M 188.00M 186.00M 151.00M
Long term debt total 9048.00M 5227.00M 6572.00M 6552.00M 6592.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -100.00M -315.00M -777.00M -883.00M 32.00M
Change to liabilities - - - -111.00M 185.00M
Total cashflows from investing activities -748.00M -315.00M -777.00M -883.00M -458.00M
Net borrowings 2498.00M -3.00M -1349.00M 1340.00M -604.00M
Total cash from financing activities -1870.00M -2660.00M -3109.00M -904.00M -1862.00M
Change to operating activities - - - -47.00M 195.00M
Net income 2673.00M 2496.00M 2344.00M 2111.00M 2034.00M
Change in cash 325.00M -54.00M -1540.00M 96.00M -119.00M
Begin period cash flow 1987.00M 2041.00M 3581.00M 3485.00M 3604.00M
End period cash flow 2312.00M 1987.00M 2041.00M 3581.00M 3485.00M
Total cash from operating activities 2904.00M 2953.00M 2353.00M 1912.00M 2213.00M
Depreciation 487.00M 497.00M 491.00M 465.00M 448.00M
Other cashflows from investing activities -96.00M -2.00M 6.00M -311.00M -13.00M
Dividends paid 889.00M 786.00M 692.00M -611.00M -474.00M
Change to inventory -199.00M -40.00M -361.00M -486.00M -366.00M
Change to account receivables -236.00M -61.00M -102.00M -137.00M -155.00M
Sale purchase of stock -3235.00M -1858.00M -1092.00M -1594.00M -743.00M
Other cashflows from financing activities -14.00M -13.00M 24.00M 1311.00M -6.00M
Change to netincome - - - -82.00M 71.00M
Capital expenditures 621.00M 655.00M 732.00M 586.00M 477.00M
Change receivables - - - -137.00M -155.00M
Cash flows other operating - - - 152.00M -4.00M
Cash and cash equivalents changes - - - 125.00M -107.00M
Change in working capital -408.00M 79.00M -512.00M -699.00M -343.00M
Stock based compensation 83.00M 74.00M 60.00M 62.00M 58.00M
Other non cash items 121.00M 145.00M 31.00M 259.00M 96.00M
Free cash flow 2283.00M 2298.00M 1621.00M 1326.00M 1736.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ZTS
Zoetis Inc		 -0.14
0.18%		 82.31 11.98 12.35 3.19 9.67 3.99 9.46
MKKGY
Merck KGaA ADR		 0.13
0.39%		 33.80 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 169.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.84 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Zoetis Inc

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

10 Sylvan Way, Parsippany, NJ, United States, 07054

973 822 7000

https://www.zoetis.com

14500

Name Title Year Born
Ms. Kristin C. Peck CEO & Director 1971
Mr. Wetteny N. Joseph Exec. VP & CFO 1972
Ms. Heidi C. Chen Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics 1967
Mr. Glenn C. David Exec. VP & Group Pres of U.S. Operations, Global Diagnostics and BioDevices 1972
Ms. Roxanne Lagano Exec. VP and Chief HR Officer & Global Operations 1965
Ms. Wafaa Mamilli EVP, Chief Digital & Tech. Officer, Group Pres for China, Brazil and Preci. Animal Health 1967
Mr. Steven Frank VP of Investor Relations NA
Mr. William Price VP & Chief Communications Officer NA
Dr. Robert J. Polzer Ph.D. Exec. VP and Pres of R&D 1969
Ms. Jeannette Ferran Astorga Exec. VP of Corp. Affairs & Communications and Chief Sustainability Officer 1975

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…